By Fineline Cube 
Sino Biopharmaceutical Limited (HKG: 1177) announced that its independently developed Category 2.3 modified new drug, TQC3302, has received clinical trial approval from China’s National Medical Products Administration (NMPA). The drug is intended for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Drug Profile
TQC3302 is a triple-combination formulation comprising ICS (inhaled corticosteroid), LAMA (long-acting muscarinic antagonist), and LABA (long-acting β2-adrenergic agonist). It was developed using Sino Biopharma’s soft mist inhalation technology platform.
Preclinical Findings
Preclinical studies have confirmed the safety of the triple-combination formulation. The product delivers medication to patients in the form of a slow-moving fine mist through mechanical actuation. Compared to conventional nebulizers or dry powder inhalers, soft mist inhalers offer a longer aerosol release time and slower velocity. This reduces drug loss in the oropharyngeal region and achieves a higher rate of pulmonary deposition.
Patient Benefits
The soft mist inhaler requires less hand-mouth coordination from patients, making it suitable for populations with administration difficulties, such as children and the elderly. This feature enhances the drug’s accessibility and usability for a broader patient population.-Fineline Info & Tech